Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 11/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 2/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4901060 | 0.89 | KDM4E (0.43) | MEN1KMT2AHIF1ANPC1RAB9A | |
| SCHEMBL4576606 | 0.88 | MEN1 (0.37) | MEN1KMT2AHIF1AALDH1A1NPC1 | |
| SCHEMBL4576040 | 0.88 | KMT2A (0.35) | MEN1KMT2AHIF1AP2RX7NPC1 | |
| SCHEMBL5545343 | 0.87 | MEN1 (0.36) | MEN1KMT2AHIF1AALDH1A1NPC1 | |
| SCHEMBL5546795 | 0.86 | TOP2A (0.35) | MEN1KMT2AHIF1A | |
| SCHEMBL4591362 | 0.86 | MEN1 (0.34) | MEN1KMT2AHIF1AALDH1A1 | |
| SCHEMBL4590898 | 0.86 | MEN1 (0.36) | MEN1KMT2AHIF1ANPC1RAB9A | |
| SCHEMBL4576778 | 0.86 | TACR1 (0.33) | MEN1KMT2AHIF1A | |
| SCHEMBL4590860 | 0.85 | MEN1 (0.34) | MEN1KMT2AHIF1AALDH1A1NPC1 | |
| SCHEMBL4591622 | 0.85 | HIF1A (0.34) | MEN1KMT2AHIF1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214527-A1 | Hiv Integrase Inhibitors | SHIONOGI & CO. LTD (JP) | 2008-09-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214527-A1 | Hiv Integrase Inhibitors | API5, ING2, SAMHD1 | MEN1 4841/4885KMT2A 682/4885HIF1A 3129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.